Upper Respiratory Infections Linked to Nonadherence to Scheduled Chemotherapy
the Cancer Therapy Advisor take:
A patient’s adherence to their chemotherapy schedule is an integral aspect to an optimal treatment outcome. A prospective cohort study led by Ahmed Taha, MD, of the Sackler Faculty of Medicine, Tel-Aviv University in Tel-Aviv, Israel, looked into the factors that led to a dose reduction, a delay in chemotherapy, or a cancellation of a patient’s planned chemotherapy.
The focus of the research was mainly delays in chemotherapy because of a mild respiratory infection during the winter. The research included 547 adult patients with solid or hematologic cancer who were undergoing chemotherapy in a cancer center during the winter of 2010 to 2011. The researchers determined that 213 of the patients followed (38.9%) experienced 306 delays in chemotherapy treatment.
The documented reasons for the delays in chemotherapy were neutropenia (84/306, 27.4%), fever or infection (73/306, 23.9%), and thrombocytopenia (26/306, 8.5%). Upper respiratory infections (OR 1.87, 95% CI 1.27–2.76), prior hospitalization, lymphopenia, and peripheral vascular disease were all found to be independent risk factors for delayed chemotherapy treatment.
Researchers conducted an adjusted analysis that analyzed nonadherence to chemotherapy only because of an infection, that analysis determined that age alone and an upper respiratory infection (OR 5.25, 95% I 2.81–9.84) were significant independent risk factors. With this knowledge, the researchers encourage clinicians to assist their patients in preventing upper respiratory infections in order to avoid delays in chemotherapy schedules.
Factors examined for dose reduction, delay in chemotherapy, or cancellation of a planned chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Opinion: Understanding the FDA's Take on Cannabidiol
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer